UK markets closed

Sarepta Therapeutics, Inc. (0L35.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
119.78-5.04 (-4.04%)
At close: 02:56PM GMT
Full screen
Previous close124.82
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Avg. volumeN/A
Market cap97.532M
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future

    With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...

  • Motley Fool

    2 Under-the-Radar Biotech Stocks to Buy in 2023

    Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).

  • Motley Fool

    2 Top Healthcare Stocks to Buy for the Long Haul

    There are many such corporations to consider on the market, but let's examine two: Guardant Health (NASDAQ: GH) and Sarepta Therapeutics (NASDAQ: SRPT). Progress in cancer research is always important as cancer is a leading cause of death worldwide. Guardant Health focuses on developing liquid biopsies -- tests that help detect signs of cancer from blood samples.